Drug news
EU approves Cyramza for treatment of Stomach/ Gastric Cancer- Eli Lilly
Cyramza (ramucirumab) from Eli lilly has now EU approval to treat patients with advanced Stomach or Gastric Oesophageal Junction Adneocarcinoma after prior chemotherapy with fluoropyrimidine and platinium as a single agent or in combination with paclitaxel. Approval was based on the potential survival benefit for patients in the RAINBOW study where Cyramza plus paclitaxel extended overall survival time to 9.6 months compared to 7.4 months with best supportive care.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.